UT Health San Antonio becomes first civilian center in South Texas to launch FDA-approved radiotherapy treatment for advanced prostate cancer

October 6, 2023

  The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers radiation treatment […]

New research led by Mays Cancer Center reveals how mutations in BRCA1 affect cancer susceptibility in women

October 6, 2023

Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has pinpointed the molecular mechanism by which a large portion of these mutations cause cancers in women. The […]

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer

October 5, 2023

Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases. The study focuses on androgen receptors (AR), which are protein molecules that help direct the development of male sexual characteristics, […]

Mays Cancer Center at UT Health San Antonio identifies possible markers for early metastatic lung cancer

October 4, 2023

Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment. The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of […]